Elisa Assay Diluent Formulation

ELISA GENERAL ASSAY DILUENT
MBS238291-100mL 100mL
EUR 210

Assay Elisa Laboratories manufactures the elisa assay diluent formulation reagents distributed by Genprice. The Elisa Assay Diluent Formulation reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Assay elisa. Other Elisa products are available in stock. Specificity: Elisa Category: Assay Group: Diluent Formulation

ELISA NEPTUNE ASSAY DILUENT
1L
EUR 720

ELISA NEPTUNE ASSAY DILUENT
5x1L
EUR 3125

General Assay Diluent
100 mL
EUR 57.5

General Assay Diluent
500 mL
EUR 227.5

General Assay Diluent
1 L
EUR 295

Assay Diluent Buffer
1 unit
EUR 3.26
Description: Assay Diluent Buffer

Assay Diluent Buffer
1 unit
EUR 15.45
Description: Assay Diluent Buffer

Diluent Formulation information

ELISA GENERAL ASSAY DILUENT
MBS239226-5x500mL 5x500mL
EUR 2240

ELISA GENERAL ASSAY DILUENT
MBS239227-1L 1L
EUR 680

ELISA GENERAL ASSAY DILUENT
MBS239227-5x1L 5x1L
EUR 2930

ELISA NEPTUNE ASSAY DILUENT
MBS239230-500mL 500mL
EUR 525

ELISA NEPTUNE ASSAY DILUENT
MBS239230-5x500mL 5x500mL
EUR 2185

ELISA NEPTUNE ASSAY DILUENT
MBS239231-1L 1L
EUR 720

ELISA NEPTUNE ASSAY DILUENT
MBS239231-5x1L 5x1L
EUR 3125

Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
DLL-0011-10ML 10mL
EUR 2995
Description: PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
DLL-0011-2ML 2mL
EUR 995
Description: PEGylated liposomes containing Hsp90 inhibitor Tanespimycin (17-AAG). Tanespimycin exhibits 100-fold higher binding affinity to HSP90 derived from tumor cells vs normal cells, and induces apoptosis, necrosis, autophagy, and mitophagy. Tanespimycin is insoluble in aqueous media. This product is a pre-formulated liposomal version of Tanespimycin which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Nutri-fly Molasses Formulation 10 x 10L - PK10
FLY1286 PK10
EUR 1289.61

Lificiguat (YC-1) Liposomes, Formulation FNT8P.2
DLL-0016-A1-10ML 10mL
EUR 2995
Description: PEGylated liposomes containing HIF-1α inhibitor Lificiguat (YC-1). Lificiguat (YC-1) is an inhibitor of Hypoxia-inducible factor-1 alpha (HIF-1 alpha). YC-1 also activates soluble guanylyl cyclase (sGC) in (NO)-independent manner. Lificiguat (YC-1) is insoluble in aqueous media. This product is a pre-formulated liposomal version of Lificiguat which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1A-100MG 10 mL
EUR 2995
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1A-10MG 1 mL
EUR 595
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1A-25MG 2.5 mL
EUR 995
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1B-100MG 10 mL
EUR 3195
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1B-10MG 1 mL
EUR 795
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.

Mirdametinib (PD0325901) Liposomes, Formulation U6-2
DLL-0008-1B-25MG 2.5 mL
EUR 1195
Description: PEGylated liposomes containing MEK inhibitor Mirdametinib (PD0325901). Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with an IC50 of 0.33 nM (cell-free assays). The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.